

Summary Report of Consolidated Financial Results

For the Nine months Period ended December 31, 2007 (Year ending March 31, 2008)



February 12, 2008

Company name: **NIPRO CORPORATION** TSE/OSE - 1st section
 Code number: 8086 URL: <http://www.nipro.co.jp/>
 Representative: Minoru Sano, President and Representative Director
 Contact: Akihiko Yamabe, Director, General Manager of Accounting & Corporate Planning Division
 TEL: (06) 6372-2331

(Note: Amounts are truncated to one million yen)

1. Financial results for the nine months ended December 31, 2007.(From April 1, 2007 to December 31, 2007)

(1) Consolidated Results of Operations

	Net Sales	Operating Income	Recurring Income	Net(Quarter) Income
	Millions of yen %	Millions of yen %	Millions of yen %	Millions of yen %
9 months ended December 31,2007	129,982 (10.8)	11,021 10.1	9,840 7.7	5,270 (38.2)
9 months ended December 31,2006	145,796 (6.6)	10,012 (5.3)	9,139 (16.6)	8,530 85.0
Year ended March 31,2007	184,362 -	13,053 -	11,355 -	8,555 -

	Earnings per Share	Diluted Earnings per Share
	Yen	Yen
9 months ended December 31,2007	83.04	-
9 months ended December 31,2006	134.31	-
Year ended March 31,2007	134.71	-

Note: The % displays show increase/decrease ratio against the same period of the previous year.

(2) Consolidated Financial Position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
9 months ended December 31,2007	344,189	121,583	34.9	1,892.83
9 months ended December 31,2006	318,836	117,638	36.5	1,831.78
Year ended March 31,2007	336,659	127,020	37.3	1,979.21

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
9 months ended December 31,2007	1,183	(19,544)	7,194	34,941
9 months ended December 31,2006	8,324	(730)	(17,931)	39,757
Year ended March 31,2007	14,488	(2,924)	(15,654)	46,109

2. Projected Consolidated Financial Results for the Year ending March 31, 2008 (From April 1, 2007 to March 31, 2008)

The figures of the projected consolidated financial results for the year ending March 31, 2008 (From April 1, 2007 to March 31, 2008), announced on November 19, 2007, have not been changed.

3. Others

- (1) Change in significant subsidiaries during the nine-month period ended December 31, 2007(Resulting in a change in scope of consolidation): Yes
Addition: 1 (Saitama Daiichi Pharmaceutical Co., Ltd.) Removal: 0
- (2) Adoption of simplified accounting treatments: None
- (3) Difference in the method of accounting treatment from the most recent fiscal year: None
(Note) More information can be found in page 4. [Qualitative information, financial statements and others] 5.
Others.

*Disclaimer regarding projection information including appropriate use of forecasted financial results, and other special notes

The projection figures shown above are based on information that was available at the time of preparation and may contain certain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstances and other developments. More information concerning these forecasts can be found on page 4 in the attachments.

1. Qualitative information on the consolidated results of operation

The situation of Japanese economy for this nine-month period generally remained in the trend of gradual expansion due to the steady capital investments, while we were afraid of a negative impact from the continuous high oil prices and the underperforming economy in the United States.

On the other hand, as we are in a drastic changing period of the medical business field, we have made effort to develop progressive medical equipments by a unique point of view and reinforce injection drug, oral drug, artificial organs and regenerative medical business to establish a worldwide brand to be a real global enterprise.

As a result, net sales for the nine months ended December 31, 2007 was 129,982 million yen, decreased 10.8% from the same period of the previous fiscal year because of our discontinuation of the Store business, which had the sales of 30,973 million yen in the same period of the previous fiscal year. The sales of Medical Equipment business was 83,281 million increased 15.9% from the same period of the previous fiscal year, the sales of Pharmaceutical business was 37,491 million yen increased 17.2% from the same period of the previous fiscal year, the sales of Glass and Materials business was 8,491 million yen decreased 16.6% from the same period of the previous fiscal year.

Operating income increased 10.1% from the same period of the previous fiscal year to 11,021 million yen and recurring income increased 7.7% from the same period of the previous fiscal year to 9,840 million yen. However, net quarter income decreased 38.2% from the same period of the previous fiscal year to 5,270 million yen due to the decrease of extraordinary profit.

2. Qualitative information on the consolidated financial position

Total assets increased 25,353 million yen to 344,189 million yen from the end of previous fiscal year. Current assets increased 6,778 million yen to 151,061 million yen and fixed assets increased 18,574 million yen to 193,128 million yen, from the end of previous fiscal year. Current assets increased mainly due to the increase in the trade notes and accounts receivable, and inventories. Fixed assets increased mainly due to the increase in buildings and structures, machinery and vehicles in tangible fixed assets.

Total liabilities increased 21,407 million yen to 22,265 million yen. Current liabilities increased 8,318 million yen to 113,715 million yen and fixed liabilities increased 13,089 million yen to 108,890 million yen, from the end of previous fiscal year. Current liabilities increased mainly due to increase in current portion of bonds and notes payable for plant and equipment, and fixed liabilities increased mainly due to increase of long-term borrowings.

Net assets increased 3,945 million yen to 121,583 million yen from the end of previous fiscal year. Earned surplus in the net assets increased 1,605 million yen to 40,293 million yen.

3. Qualitative information on the state of the consolidated cash flow

Cash and cash equivalents at the end of the period ended in December 31, 2007 amounted to 34,941 million yen. The state of each cash flow in the period was as follows.

(Cash flow in operating activities)

Cash flow provided by operating activities was 1,183 million yen. Major items of cash inflow were mainly net income before adjustment of taxes of 9,253 million yen, and depreciation and amortization of 10,886 million yen. Major items of cash outflow were increase of trade note and account receivables of 6,097 million yen, payment for corporate income taxes of 10,029 million yen.

(Cash flow in investing activities)

Cash flow used in investing activities was 19,544 million yen. The main payment was for acquisition of fixed assets of 14,863 million yen.

(Cash flow in financing activities)

Cash flow provided by financing activities was 7,194 million yen. The details of proceeds were mainly the proceeds from long-term borrowings of 29,037 million yen and the details of payment were mainly repayment of the long-term borrowings of 20,256 million yen and the payments for dividends of 4,100 million yen.

4. Qualitative information on the projected consolidated financial results

The business environment is anticipated to remain severe due to worry about the risks concerning the falling situation in the stock exchange market and exchange rate fluctuation. We, however, continuously endeavor to develop new products, as well as to reinforce the production capacity and selling capability in order to enhance our revenues.

Thus, the figures of the projected consolidated financial results for the year ending March 31, 2008 (From April 1, 2007 to March 31, 2008) announced on November 19, 2007, have not been changed.

5. Others

(1) Change in significant subsidiaries during the nine-month period ended December 31, 2007(Resulting in a change in scope of consolidation): Yes

Addition: 1 (Saitama Daiichi Pharmaceutical Co., Ltd.)

Saitama Daiichi Pharmaceutical Co., Ltd. was included in the scope of consolidation because of acquisition of the shares.

(2) Adoption of simplified accounting treatments: None

(3) Difference in the method of accounting treatment from the most recent fiscal year: None

6. Summary of Quarter Consolidated Financial Statements

(1) Summary of Quarter Consolidated Balance Sheets for the Nine Months Period ended December 31, 2007 (Year ending March 31, 2008)

(Note: Amounts are truncated to one million yen)

Account	As of December 31, 2006		As of December 31, 2007		Change in amount		As of March 31, 2007	
	Amount	Ratio	Amount	Ratio	Amount	Change Ratio	Amount	Ratio
(ASSETS)		%		%		%		%
Current Assets	<u>144,282</u>	45.3	<u>151,061</u>	43.9	<u>6,778</u>	4.7	<u>147,233</u>	43.7
Cash on hand and in banks	45,021		36,754		(8,266)		47,934	
Trade notes and accounts receivable	51,900		58,787		6,887		50,972	
Inventories	39,660		46,232		6,571		40,213	
Deferred tax assets	3,472		2,976		(496)		3,033	
Other current assets	4,757		6,797		2,040		5,581	
Allowance for doubtful accounts	(529)		(487)		42		(501)	
Fixed Assets	<u>174,553</u>	54.7	<u>193,128</u>	56.1	<u>18,574</u>	10.6	<u>189,426</u>	56.3
Tangible fixed assets	<u>100,899</u>	31.6	<u>118,405</u>	34.4	<u>17,505</u>	17.3	<u>104,881</u>	31.2
Buildings and structures	36,685		45,643		8,958		38,113	
Machinery and vehicles	30,521		37,890		7,369		31,105	
Land	17,997		19,394		1,397		18,032	
Construction in progress	11,159		10,502		(656)		12,856	
Others	4,536		4,973		436		4,773	
Intangible fixed assets	<u>1,832</u>	0.6	<u>3,009</u>	0.9	<u>1,177</u>	64.2	<u>1,902</u>	0.6
Goodwill	245		1,275		1,029		240	
Others	1,586		1,734		147		1,661	
Investments and other assets	<u>71,820</u>	22.5	<u>71,712</u>	20.8	<u>(107)</u>	(0.2)	<u>82,642</u>	24.5
Investment securities	65,808		66,927		1,118		77,304	
Long-term loans receivable	345		234		(110)		303	
Deferred tax assets	395		85		(310)		61	
Lease deposits	4,856		4,545		(310)		4,791	
Other assets	3,455		2,971		(483)		3,198	
Allowance for doubtful accounts	(3,040)		(3,052)		(12)		(3,017)	
Total Assets	318,836	100.0	344,189	100.0	25,353	8.0	336,659	100.0

(Note: Amounts are truncated to one million yen)

Account	As of December 31, 2006		As of December 31, 2007		Change in amount		As of March 31, 2007	
	Amount	Ratio	Amount	Ratio	Amount	Change Ratio	Amount	Ratio
(LIABILITIES)		%		%		%		%
Current liabilities	<u>105,396</u>	33.1	<u>113,715</u>	33.1	<u>8,318</u>	7.9	<u>104,104</u>	30.9
Trade notes and accounts payable	28,350		30,757		2,407		26,547	
Short-term borrowings	53,370		47,864		(5,505)		50,209	
Current portion of bonds	60		10,160		10,100		60	
Other payables	3,874		5,020		1,146		6,123	
Accrued income taxes	7,362		2,469		(4,892)		8,404	
Allowance for bonuses payable	2,433		1,303		(1,129)		1,461	
Allowance for bonuses payable for directors and corporate auditors	-		3		3		230	
Allowance for loss on clearance of business Notes payable for plant and equipment	1,954		1,954		-		1,954	
Notes payable for plant and equipment	3,448		8,971		5,523		3,655	
Others	4,543		5,208		665		5,457	
Fixed liabilities	<u>95,801</u>	30.0	<u>108,890</u>	31.6	<u>13,089</u>	13.7	<u>105,534</u>	31.4
Bonds	31,480		21,320		(10,160)		31,450	
Convertible bond type bonds stock acquisition rights	14,000		14,000		-		14,000	
Long-term borrowings	33,240		56,526		23,286		38,765	
Deferred tax liabilities	12,991		12,838		(152)		17,417	
Accrued pension and severance cost	2,761		2,344		(416)		2,564	
Accrued severance indemnity for directors and corporate auditors	-		510		510		-	
Other fixed liabilities	1,328		1,351		22		1,336	
Total liabilities	201,197	63.1	222,605	64.7	21,407	10.6	209,639	62.3
(Net Assets)								
Shareholders' Equity	<u>96,606</u>	30.3	<u>98,141</u>	28.5	<u>1,535</u>	1.6	<u>97,044</u>	28.8
Capital	28,663	9.0	28,663	8.3	-	-	28,663	8.5
Capital surplus	29,973	9.4	29,975	8.7	2	0.0	29,973	8.9
Earned surplus	38,687	12.1	40,293	11.7	1,605	4.2	39,148	11.6
Treasury stock	(717)	(0.2)	(790)	(0.2)	(72)	10.1	(741)	(0.2)
Valuation and translation differences	<u>19,704</u>	6.2	<u>21,987</u>	6.4	<u>2,283</u>	11.6	<u>28,606</u>	8.5
Valuation differences of other securities	22,864	7.2	23,401	6.8	536	2.3	29,883	8.9
Foreign currency translation adjustments	(3,160)	(1.0)	(1,413)	(0.4)	1,746	(55.3)	(1,276)	(0.4)
Minority interests	<u>1,327</u>	0.4	<u>1,454</u>	0.4	<u>126</u>	9.5	<u>1,369</u>	0.4
Total Net Assets	117,638	36.9	121,583	35.3	3,945	3.4	127,020	37.7
Total Liabilities and Net Assets	318,836	100.0	344,189	100.0	25,353	8.0	336,659	100.0

(2) Summary of Quarter Consolidated Statements of Income for the Nine Months Period ended December 31, 2007 (Year ending March 31, 2008)

(Note: Amounts are truncated to one million yen)

Account	Previous Period (From April 1, 2006 To December 31, 2006)		Current Period (From April 1, 2007 To December 31, 2007)		Change in amount		Previous Period (From April 1, 2006 To March 31, 2007)	
	Amount	Ratio	Amount	Ratio	Amount	Change Ratio	Amount	Ratio
Net sales	145,796	100.0	129,982	100.0	(15,813)	(10.8)	184,362	100.0
Cost of goods sold	105,334	72.2	92,813	71.4	(12,520)	(11.9)	132,142	71.7
Gross profit	40,461	27.8	37,168	28.6	(3,293)	(8.1)	52,220	28.3
Selling, general and administrative expenses	30,449	20.9	26,147	20.1	(4,302)	(14.1)	39,167	21.2
Operating income	10,012	6.9	11,021	8.5	1,009	10.1	13,053	7.1
Non-operating income	<u>1,526</u>	1.0	<u>1,338</u>	1.0	<u>(188)</u>	(12.4)	<u>1,657</u>	0.9
Interest income	203		319		116		308	
Dividend income	558		613		54		560	
Exchange gain	395		-		(395)		313	
Others	369		404		35		475	
Non-operating expenses	<u>2,399</u>	1.6	<u>2,519</u>	1.9	<u>(120)</u>	5.0	<u>3,355</u>	1.8
Interest expenses	1,200		1,395		194		1,645	
Depreciation	281		318		37		381	
Exchange loss	-		193		193		-	
Equity in loss of affiliate	534		471		(62)		791	
Others	383		141		(241)		537	
Recurring income	9,139	6.3	9,840	7.6	700	7.7	11,355	6.2
Extraordinary gains	<u>13,425</u>	9.2	<u>316</u>	0.2	<u>(13,108)</u>		<u>13,660</u>	7.4
Gain on sale of fixed assets	22		58		35		30	
Governmental subsidies received	666		4		(661)		661	
Gain on sale of investment securities	12,706		-		(12,706)		12,706	
Life insurance income	-		191		191		-	
Others	30		62		32		261	
Extraordinary losses	<u>7,353</u>	5.1	<u>903</u>	0.7	<u>(6,450)</u>		<u>8,240</u>	4.5
Loss on sale and disposal of fixed assets	271		171		(100)		516	
Impairment loss on fixed assets	1,286		-		(1,286)		1,286	
Allowance for loss on clearance of business	1,954		-		(1,954)		1,954	
Loss on investment securities	268		-		(268)		268	
Loss on disposal of inventories	112		48		(64)		253	
Abnormal manufacturing cost	177		96		(81)		246	
Advanced depreciation on fixed assets	654		3		(650)		650	
Allowance for doubtful debts	2,307		12		(2,295)		2,361	
Allowance for accrued severance indemnity for directors and corporate auditors in prior years	-		471		471		-	
Others	318		99		(218)		703	
Net(Quarter) income before adjustment of taxes	15,212	10.4	9,253	7.1	5,958	(39.2)	16,775	9.1
Corporate, inhabitants and enterprise taxes	9,305	6.3	3,889	3.0	(5,416)		10,059	5.5
Adjustment for deferred taxes	(2,625)	(1.8)	9	0.0	2,635		(1,873)	(1.0)
Minority shareholders' share in net income of consolidated subsidiaries	1	0.0	83	0.0	82		33	0.0
Net(Quarter) income	8,530	5.9	5,270	4.1	(3,259)	(38.2)	8,555	4.6

(3) Consolidated Statement of Shareholders' Equity

Previous period (From April 1, 2006 to December 31, 2006)

(Note: Amounts are truncated to one million yen)

	Shareholders' equity				
	Capital	Capital surplus	Earned surplus	Treasury stock	Total shareholders' equity
Balance at March 31, 2006	28,663	29,972	34,545	(648)	92,532
Increase (decrease) during the period					
Dividend of surplus			(4,096)		(4,096)
Bonuses to directors and corporate auditors			(91)		(91)
Net(Quarter) income			8,530		8,530
Acquisition of treasury stock				(76)	(76)
Disposal of treasury stock		1		8	9
Decrease in earned surplus due to addition of consolidated subsidiaries			(201)		(201)
Increase (decrease) of the items other than shareholders' equity during the period					-
Net increase (decrease) during the period	-	1	4,141	(68)	(4,074)
Balance at December 31, 2006	28,663	29,973	38,687	(717)	96,606

	Valuation and translation differences			Minority interests	Total net assets
	Valuation differences of other securities	Foreign currency translation adjustments	Total valuation and translation differences		
Balance at March 31, 2006	25,563	(5,705)	19,858	1,612	114,003
Increase (decrease) during the period					
Dividend of surplus			-		(4,096)
Bonuses to directors and corporate auditors			-		(91)
Net(Quarter) income			-		8,530
Acquisition of treasury stock			-		(76)
Disposal of treasury stock			-		9
Decrease in earned surplus due to addition of consolidated subsidiaries			-		(201)
Increase (decrease) of the items other than shareholders' equity during the period	(2,699)	2,544	(154)	(284)	(439)
Net increase (decrease) during the period	(2,699)	2,544	(154)	(284)	3,635
Balance at December 31, 2006	22,864	(3,160)	19,704	1,327	117,638

Current period (From April 1, 2007 to December 31, 2007)

(Note: Amounts are truncated to one million yen)

	Shareholders' equity				
	Capital	Capital surplus	Earned surplus	Treasury stock	Total shareholders' equity
Balance at March 31, 2007	28,663	29,973	39,148	(741)	97,044
Increase (decrease) during the period					
Dividend of surplus			(4,126)		(4,126)
Net(Quarter) income			5,270		5,270
Acquisition of treasury stock				(56)	(56)
Disposal of treasury stock		2		7	9
Increase (decrease) of the items other than shareholders' equity during the period					-
Net increase (decrease) during the period	-	2	1,144	(48)	1,097
Balance at December 31, 2007	28,663	29,975	40,293	(790)	98,141

	Valuation and translation differences			Minority interests	Total net assets
	Valuation differences of other securities	Foreign currency translation adjustments	Total valuation and translation differences		
Balance at March 31, 2007	29,883	(1,276)	28,606	1,369	127,020
Increase (decrease) during the period					
Dividend of surplus			-		(4,126)
Net(Quarter) income			-		5,270
Acquisition of treasury stock			-		(56)
Disposal of treasury stock			-		9
Increase (decrease) of the items other than shareholders' equity during the period	(6,482)	(136)	(6,619)	84	(6,534)
Net increase (decrease) during the period	(6,482)	(136)	(6,619)	84	(5,436)
Balance at December 31, 2007	23,401	(1,413)	21,987	1,454	121,583

Previous period (From April 1, 2006 to March 31, 2007)

(Note: Amounts are truncated to one million yen)

	Shareholders' equity				
	Capital	Capital surplus	Earned surplus	Treasury stock	Total shareholders' equity
Balance at March 31, 2006	28,663	29,972	34,545	(648)	92,532
Increase (decrease) during the period					
Dividend of surplus			(4,096)		(4,096)
Bonuses to directors and corporate auditors			(91)		(91)
Net income			8,555		8,555
Acquisition of treasury stock				(101)	(101)
Disposal of treasury stock		1		9	10
Increase in earned surplus due to divestiture of consolidated subsidiaries			436		436
Decrease in earned surplus due to addition of consolidated subsidiaries			(201)		(201)
Increase (decrease) of the items other than shareholders' equity during the period					-
Net increase (decrease) during the period	-	1	4,602	(92)	4,512
Balance at March 31, 2007	28,663	29,973	39,148	(741)	97,044

	Valuation and translation differences			Minority interests	Total net assets
	Valuation differences of other securities	Foreign currency translation adjustments	Total valuation and translation differences		
Balance at March 31, 2006	25,563	(5,705)	19,858	1,612	114,003
Increase (decrease) during the period					
Dividend of surplus			-		(4,096)
Bonuses to directors and corporate auditors			-		(91)
Net income			-		8,555
Acquisition of treasury stock			-		(101)
Disposal of treasury stock			-		10
Increase in earned surplus due to divestiture of consolidated subsidiaries			-		436
Decrease in earned surplus due to addition of consolidated subsidiaries			-		(201)
Increase (decrease) of the items other than shareholders' equity during the period	4,319	4,428	8,748	(243)	8,505
Net increase (decrease) during the period	4,319	4,428	8,748	(243)	13,017
Balance at March 31, 2007	29,883	(1,276)	28,606	1,369	127,020

(4) Summary of Quarter Consolidated Statements of Cash Flow

(Note: Amounts are truncated to one million yen)

	Previous Period (From April 1, 2006 To December 31, 2006)	Current Period (From April 1, 2007 To December 31, 2007)	Previous Period (From April 1, 2006 To March 31, 2007)
Division	Amount	Amount	Amount
Cash flows from operating activities			
Net income before adjustment for taxes	15,212	9,253	16,775
Depreciation and amortization	9,041	10,886	12,469
Impairment loss on fixed assets	1,286	-	1,286
Amortization of goodwill	115	181	129
Equity in loss of affiliate	534	471	791
Allowance for doubtful debts	2,307	-	2,361
Allowance for loss on clearance of business	1,954	-	1,954
Increase (decrease) in allowance for doubtful accounts	35	19	(92)
Interest and dividend income	(762)	(933)	(868)
Interest expenses	1,200	1,395	1,645
Exchange loss (gain)	(34)	(59)	(68)
Gain on sales of shares of subsidiary company	(12,706)	-	(12,706)
Decrease (increase) in trade receivables	(4,574)	(6,097)	(2,186)
Decrease (increase) in inventories	(3,186)	(4,995)	(3,061)
Increase (decrease) in trade payables	601	1,804	(1,982)
Decrease (increase) in other assets	(700)	364	(565)
Increase (decrease) in other liabilities	1,739	(1,091)	2,678
Bonuses to directors and corporate auditors	(96)	-	(96)
Other non-operating income/expenses and extraordinary gains/losses	773	(77)	882
Subtotal	12,740	11,120	19,347
Interest and dividends received	843	916	830
Interest paid	(1,266)	(1,320)	(1,697)
Other revenues	1,472	731	1,590
Other expenditures	(212)	(234)	(262)
Income taxes paid	(5,253)	(10,029)	(5,320)
Cash flows from operating activities	8,324	1,183	14,488
Cash flows from investing activities			
Deposits in time deposits	(4,263)	(1,445)	(5,792)
Proceeds from matured time deposits	2,677	1,446	7,665
Payments for purchases of securities	(2,244)	(1,014)	(2,244)
Proceeds from sales of securities	24	-	24
Payments for acquisition of shares with change In scope of consolidated subsidiary	(517)	(3,125)	(1,220)
Proceeds from sales of shares with change in scope of consolidated subsidiary	19,372	-	19,372
Payments for acquisition of fixed assets	(14,944)	(14,863)	(19,911)
Proceeds from sales of fixed assets	20	155	273
Increase(decrease) in short-term lending	(833)	(784)	(1,078)
Collections of loans receivable	48	59	59
Expenditures for other investments	(112)	(1)	(112)
Revenues from other investments	40	29	40
Cash flows from investing activities	(730)	(19,544)	(2,924)
Cash flows from financing activities			
Net increase (decrease) in short-term borrowings	5,749	2,624	121
Net increase (decrease) in commercial paper	(9,000)	-	(9,000)
Proceeds from long-term borrowings	9,984	29,037	20,853
Repayment of long-term borrowings	(10,299)	(20,256)	(13,181)
Payments for redemption of bonds	(10,030)	(30)	(10,060)
Proceeds from issuance of shares	-	3	-
Proceeds from disposal of treasury stock	9	9	10
Payments for acquisitions of treasury stock	(76)	(56)	(101)
Repayments of finance lease obligations	(205)	(23)	(205)
Payments for dividends	(4,062)	(4,100)	(4,090)
Other payments	(0)	(14)	(0)
Cash flows from financing activities	(17,931)	7,194	(15,654)
Effect of exchange rate changes on cash and cash equivalents	102	(2)	208
Increase (decrease) in cash and cash equivalents	(10,234)	(11,168)	(3,881)
Balance of cash and cash equivalents at the beginning of the period	49,914	46,109	49,914
Increase in cash and cash equivalents due to inclusion of new subsidiary in consolidation	77	-	77
Balance of cash and cash equivalents at the end of the period	39,757	34,941	46,109

(5) Segment information

[Segment information by business category]

Previous period (From April 1, 2006 to December 31, 2006) (Note: Amounts are truncated to one million yen)

	Medical Equipment	Pharmaceutical	Glass & Materials	Store	Other	Total	Eliminations /Corporate	Consolidated
Net sales								
(1)Sales to third parties	71,827	31,995	10,186	30,973	813	145,796	-	145,796
(2)Inter-segment sales and transfers	3	-	2,538	-	204	2,746	(2,746)	-
Total	71,831	31,995	12,724	30,973	1,018	148,542	(2,746)	145,796
Operating expenses	61,305	29,574	11,326	30,702	865	133,774	2,009	135,784
Operating income(loss)	10,525	2,421	1,398	270	152	14,767	(4,755)	10,012

Current period (From April 1, 2007 to December 31, 2007) (Note: Amounts are truncated to one million yen)

	Medical Equipment	Pharmaceutical	Glass & Materials	Other	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	83,281	37,491	8,491	718	129,982	-	129,982
(2)Inter-segment sales and transfers	-	-	2,393	51	2,444	(2,444)	-
Total	83,281	37,491	10,884	769	132,426	(2,444)	129,982
Operating expenses	70,882	34,610	9,509	768	115,771	3,189	118,960
Operating income(loss)	12,398	2,880	1,374	1	16,655	(5,633)	11,021

Previous period (From April 1, 2006 to March 31, 2007) (Note: Amounts are truncated to one million yen)

	Medical Equipment	Pharmaceutical	Glass & Materials	Store	Other	Total	Eliminations /Corporate	Consolidated
Net sales								
(1)Sales to third parties	97,300	42,152	12,918	30,973	1,017	184,362	-	184,362
(2)Inter-segment sales and transfers	3	-	3,445	-	220	3,668	(3,668)	-
Total	97,303	42,152	16,364	30,973	1,238	188,031	(3,668)	184,362
Operating expenses	82,970	38,854	14,498	30,702	1,087	168,113	3,195	171,309
Operating income(loss)	14,333	3,298	1,865	270	150	19,918	(6,864)	13,053

- (Notes) 1. Classification of business categories and main products in each business category
 Business categories are classified based on the proximity in terms of purposes and manners of usage of the products in the market.
 Main products belonging to each business categories are as follows:

Business category	Main products and commodities
Medical Equipment	Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets, etc
Pharmaceutical	Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysate solution, and circulatory drugs, etc.
Glass & Materials	Glass for pharmaceutical containers, glass for thermos bottles, glass for lighting purposes, stoppers for plastic containers and rubber stoppers, etc.
Store	Fresh meat and fish, vegetables, fruits, processed food, daily foods, frozen foods, general groceries and medicine, etc.
Other	Machinery for manufacture of medical equipment and real estate rental income, etc.

2. Operating expenses of "Eliminations/Corporate" for the consolidated accounting periods of the nine months ended December 31, 2006, the nine months ended December 31, 2007, and the year ended March 31, 2007 included unallocated corporate costs of 4,755 million yen, 5,633 million yen, and 6,864 million yen respectively.

The unallocated corporate costs consisted primarily of the parent company's research and development costs and headquarters administration costs.

[Segment information by geographical area]

Previous period (From April 1, 2006 to December 31, 2006) (Note: Amounts are truncated to one million yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	125,604	12,375	5,139	2,676	145,796	-	145,796
(2)Inter-segment sales and transfers	18,017	519	3	9,022	27,563	(27,563)	-
Total	143,621	12,894	5,143	11,699	173,359	(27,563)	145,796
Operating expenses	128,571	13,482	4,915	11,199	158,168	(22,384)	135,784
Operating income(loss)	15,050	(587)	227	500	15,191	(5,179)	10,012

Current period (From April 1, 2007 to December 31, 2007) (Note: Amounts are truncated to one million yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	103,285	15,305	6,759	4,631	129,982	-	129,982
(2)Inter-segment sales and transfers	21,082	939	4	10,395	32,422	(32,422)	-
Total	124,368	16,244	6,764	15,027	162,404	(32,422)	129,982
Operating expenses	106,929	17,126	6,462	14,317	144,835	(25,874)	118,960
Operating income(loss)	17,439	(882)	302	709	17,569	(6,547)	11,021

Previous period (From April 1, 2006 to March 31, 2007) (Note: Amounts are truncated to one million yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	156,042	17,382	7,102	3,835	184,362	-	184,362
(2)Inter-segment sales and transfers	23,610	804	86	12,373	36,875	(36,875)	-
Total	179,653	18,186	7,188	16,208	221,238	(36,875)	184,362
Operating expenses	159,255	19,133	7,050	15,755	201,193	(29,884)	171,309
Operating income(loss)	20,398	(946)	138	453	20,044	(6,991)	13,053

(Note) 1. Operating expenses of "Eliminations/Corporate" for the consolidated accounting periods of the nine months ended December 31, 2006, the nine months ended December 31, 2007, and the year ended March 31, 2007 included unallocated corporate costs of 4,755 million yen, 5,633 million yen, and 6,864 million yen respectively.

The unallocated corporate costs consisted primarily of the parent company's research and development costs and headquarters administration costs.

2. Classification of countries or areas is based on geographical proximity.

3. The major countries included in each geographical area are as follows:

America..... The United States of America and Brazil

Europe..... Belgium

Asia..... China, Thailand and Singapore

[Overseas Sales]

Previous period (From April 1, 2006 to December 31, 2006) (Note: Amounts are truncated to one million yen)

	America	Europe	Asia	Total
1. Overseas sales	23,237	10,867	5,404	39,508
2. Consolidated net sales				145,796
3. Percentage of overseas sales to consolidated net sales (%)	15.9%	7.5%	3.7%	27.1%

Current period (From April 1, 2007 to December 31, 2007) (Note: Amounts are truncated to one million yen)

	America	Europe	Asia	Total
1. Overseas sales	26,645	14,410	8,207	49,263
2. Consolidated net sales				129,982
3. Percentage of overseas sales to consolidated net sales (%)	20.5%	11.1%	6.3%	37.9%

Previous period (From April 1, 2006 to March 31, 2007) (Note: Amounts are truncated to one million yen)

	America	Europe	Asia	Total
1. Overseas sales	31,899	15,071	7,567	54,538
2. Consolidated net sales				184,362
3. Percentage of overseas sales to consolidated net sales (%)	17.3%	8.2%	4.1%	29.6%

(Notes) 1. Overseas sales represent those of the Company and the consolidated subsidiaries to countries and areas outside of Japan

2. Classification of countries or areas is based on geographical proximity.

3. The major countries included in each geographical area are as follows:

America..... The United States of America, Canada and Brazil

Europe..... Belgium, Denmark and Germany

Asia..... China, India, Indonesia, Taiwan and Thailand

7. Production, Orders received and Sales

(1) Production

(Note: Amounts are truncated to one million yen)

Business segment	Previous Period (From April 1, 2006 To December 31, 2006)		Current Period (From April 1, 2007 To December 31, 2007)		Previous Period (From April 1, 2006 To March 31, 2007)	
	Amount produced	Ratio of change from the previous period (%)	Amount produced	Ratio of change from the previous period (%)	Amount produced	Ratio of change from the previous period (%)
Medical Equipment	54,215	8.7	62,670	15.6	73,011	11.5
Pharmaceutical	30,870	15.7	35,715	15.7	41,744	16.4
Glass & Materials	2,653	6.5	2,349	(11.5)	3,253	(4.8)
Other	502	2.6	1,151	129.2	700	(23.3)
Total	88,242	11.0	101,886	15.5	118,709	12.4

- (Notes) 1. Amounts produced are calculated based on average selling prices.
 2. The above amounts are after eliminations of the inter-segment transactions.
 3. The above amounts do not include the related consumption taxes etc.

(2) Orders received

Since we adopt the production system based on estimated orders, there is nothing applicable hereto regarding the amount and the balance of orders received.

(3) Sales

(Note: Amounts are truncated to one million yen)

Business segment	Previous Period (From April 1, 2006 To December 31, 2006)		Current Period (From April 1, 2007 To December 31, 2007)		Previous Period (From April 1, 2006 To March 31, 2007)	
	Amount sold	Ratio of change from the previous period (%)	Amount sold	Ratio of change from the previous period (%)	Amount sold	Ratio of change from the previous period (%)
Medical Equipment	71,827	5.7	83,281	15.9	97,300	7.1
Pharmaceutical	31,995	22.1	37,491	17.2	42,152	19.7
Glass & Materials	10,186	17.1	8,491	(16.6)	12,918	8.3
Store	30,973	(40.7)	-	-	30,973	(54.0)
Other	813	(17.2)	718	(11.6)	1,017	(33.0)
Total	145,796	(6.6)	129,982	(10.8)	184,362	(10.9)

- (Notes) 1. The above amounts are after eliminations of the intersegment transactions.
 2. The above amounts do not include the related consumption taxes etc.